Clinical Trials Logo

Sclerosis clinical trials

View clinical trials related to Sclerosis.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04825613 No longer available - Clinical trials for Primary Lateral Sclerosis, Adult, 1

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

Start date: n/a
Phase:
Study type: Expanded Access

This Individual Patient Expanded Access IND has been created as requested by an 83-year-old man who suffers Primary Lateral Sclerosis and for which the drugs currently approved are not providing an improvement over the progression of this disease.

NCT ID: NCT04681118 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in the BCT-002-US study

NCT ID: NCT04514952 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

Start date: n/a
Phase:
Study type: Expanded Access

The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS). Stem cells have become a promising tool for the treatment of inflammatory and neurodegenerative conditions, including autoimmune diseases, traumatic brain injury, Parkinson's disease, and Alzheimer's disease.

NCT ID: NCT03822858 No longer available - Multiple Sclerosis Clinical Trials

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

Start date: n/a
Phase:
Study type: Expanded Access

To give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial.

NCT ID: NCT03537807 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

Start date: n/a
Phase:
Study type: Expanded Access

This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive benefit from treatment with an alternative oral formulation of riluzole.

NCT ID: NCT02807285 No longer available - Multiple Sclerosis Clinical Trials

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States (U.S.) for the indication of PPMS.